Home/Pipeline/AB1001

AB1001

Vitiligo

Phase 1 CompletedInvestigational New Drug

Key Facts

Indication

Vitiligo

Phase

Phase 1 Completed

Status

Investigational New Drug

Company

Ahammune Biosciences

About Ahammune Biosciences

Ahammune Biosciences develops targeted small molecule therapies for chronic skin diseases, with a lead program for vitiligo that has completed Phase 1 trials.

View full company profile

Therapeutic Areas

Immunology

Other Vitiligo Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
Adimune	Aditxt	Preclinical	Active
Vitiligo Candidate	Teva	Phase 2	Active
Therapeutic Vaccine	2A Pharma	Pre-clinical	Active
CGB-600	CAGE Bio	Phase 2	Active
Vitiligo Trial	Well Pharma Medical Research	Not Specified	Active
Novel Immunology Candidate	Teva Pharmaceutical Industries	Phase 2	Active
Opzelura (ruxolitinib cream)	Incyte	Marketed	Active
Topical Roflumilast Foam 0.3%	Arcutis Biotherapeutics	Phase 2	Proof-of-concept ongoing
SCENESSE® (afamelanotide)	Clinuvel Pharmaceuticals	Phase III	Active (CUV156)
EB06	Edesa Biotech	Phase 1	Active